

Original Article

## Correlation of *cagA* positive *Helicobacter pylori* Infection with clinical outcomes in Alzahra hospital, Isfahan, Iran

Hajieh Ghasemian Safaei\*, Hamid Tavakkoli\*\*, Ali Mojtahedi\*\*\*, Rasoul Salehei\*\*\*\*, Bahram Soleimani\*\*\*\*\*, Ebtehaj Pishva\*\*\*\*\*

### Abstract

**BACKGROUND:** *Helicobacter pylori* causes chronic active gastritis, peptic ulcer, non-cardia gastric cancer and mucosal-associated lymphoid tissue (MALT) lymphoma. Different genotypes of *Helicobacter pylori* are confirmed from disease geographical areas. Its association with clinical disease remained controversial. The aim of the present study was to investigate the relationship of the *cagA* genotype of *Helicobacter pylori* isolates with clinical manifestations and its relation to age and sex of patients.

**METHODS:** A total of 100 patients (60 male and 40 female) biopsy specimens were obtained from 3 groups of patients (40 chronic active gastritis, 40 duodenal ulcers and 20 non-gastric gastric cancers). Biopsies were cultured on specific medium and after growth colonies were confirmed as *Helicobacter pylori*. DNA extraction and polymerase chain reaction (PCR) were used to detect the presence or absence of *cagA* gene.

**RESULTS:** From a total of 100 positive samples of *H. pylori*, *cagA* genes were detected in 68% of patients and 32% of samples were negative. Mean age of normal gastritis, duodenal ulcer and gastric adenocarcinoma was 44.94, 44.97 and 67.5 years, respectively.

**CONCLUSIONS:** The present study showed no significant relationship between *cagA* genotype of *H. pylori* and chronic active gastritis, duodenal ulcer and non-cardia gastric cancer as well as sex of patients. But, in gastric adenocarcinoma, there was significant discrepancy between ages of patients in comparison with the other two groups.

**KEY WORDS:** *Helicobacter pylori*, *cagA*, virulence factors.

JRMS 2008; 13(4): 196-201

**H**elicobacter *pylori* are a major etiological agent in a range of gastroduodenal diseases including chronic active gastritis, peptic ulcer, gastric cancer, and lymphoma.<sup>1-3</sup> Although *H. pylori* infection always results in histological gastritis, only minorities of infected subjects develop an associated clinical disease.<sup>1,4,5</sup> *H. pylori* infection has world

wide distribution, and its prevalence ranges from 25% in developed countries to more than 90% in developing areas.<sup>4</sup> It has heterogeneous genotypes and phenotypes. The clinical outcome of *H. pylori* infection is proposed to be linked to certain strains such as the vacuolating cytotoxin (*vacA*) and the cytotoxin-associated gene (*cagA*).<sup>6,7</sup> *cagA* is considered

\*Assistant Professor, Department of Microbiology, Isfahan University of Medical Sciences, Isfahan, Iran.  
e-mail: ghasemian@med.mui.ac.ir (Corresponding Author)

\*\*Assistant Professor, Department of Gastroenterology, Isfahan University of Medical Sciences, Isfahan, Iran.

\*\*\*Assistant Professor, Department of Microbiology, Guilan University of Medical Sciences, Guilan, Iran.

\*\*\*\*Associate Professor, Department of Molecular Biology, IUMS, Isfahan, Iran.

\*\*\*\*\*Associate Professor, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran.

\*\*\*\*\*Associate Professor, Department of Microbiology, Isfahan University of Medical Sciences, Isfahan, Iran.

as a marker for the presence of the cluster of genes (pathogenicity island) of about 35 kilo base pairs,<sup>8-10</sup> and present in more than 50% of the *H. pylori* strains and encodes the 120–140 KDa. It is now appreciated that the *cagA* gene product is not itself a virulence factor, but the gene is a member of a pathogenicity island, which do contribute to bacterial pathogenicity.<sup>2</sup> Several genes of this *cag* island, such as *picB*, encode proteins that enhance the virulence of the strain by increasing interleukin 8 in gastric epithelial cells and mucosal inflammation.<sup>11,12</sup> *cagA* is related to virulence of the *H. pylori* strain and is associated with peptic ulcer, and gastric malignancy in some populations.<sup>13</sup> Although *H. pylori* infection is very common, geographical distribution of different subtypes exists.<sup>5,12,14</sup> The association between genotypes of *H. pylori* and clinical diseases remained controversial,<sup>9</sup> but study on genes variation of *H. pylori* not only is important for predicting the clinical outcome, also, for better understanding of microorganism distribution in all of the world and its evolutionary regions. We do not have enough information about distribution of *cagA* genotypes of *H. pylori* strains isolated from patients with different clinical symptoms in IRAN. So, the aim of the present study was to determine the *cagA* genotypes of *H. pylori* isolated from patients and its association with chronic active gastritis, duodenal ulcer and non-cardia gastric cancer.

## Methods

### *Patients and Helicobacter pylori isolates*

Between May 2004 and December 2005, from 164 patients referred to Alzahra hospital in Isfahan, Iran, attending an open access endoscopy service after obtaining informed consent for the investigation of gastritis (diagnosed as histological gastritis without peptic ulcer, gastric cancer or any esophageal disease such as gastroesophageal reflux and esophageal cancer), non-ulcer dyspepsia, duodenal ulcer (detected by endoscopy) and non-cardia gastric cancer (detected by endoscopic view and pathologic confirmation) had mucosal biopsies taken from the prepyloric and incisura before

receiving anti *H. pylori* treatment. We took one specimen for a rapid urease test (RUT), and one specimen for culture that were sent to microbiology laboratory in normal saline. Among 164 samples, 64 samples were excluded from our study, because 18 samples were contaminated with molds after culture in medium (including 8 samples that were RUT negative and culture negative and 10 samples that were RUT positive and culture negative), and 29 samples were RUT positive and culture negative and 17 samples were RUT negative and culture negative. So, we had 100 biopsy samples (60 males and 40 females), from which 40 samples were from gastritis, 40 samples from duodenal ulcer and 20 samples were from gastric adenocarcinoma. After each endoscopic examination, endoscopes were cleaned and washed with Cidex solution for 30 minutes. A new autoclaved biopsy forceps was used for each patient.

### *Isolation of H. pylori from biopsy samples*

Biopsy samples that were sent with sterile normal saline to microbiology laboratory, cultured directly on Columbia agar medium supplemented with 10% fetal calf serum, 5% blood and 10 µg/ml trimethoprim, 6 µg/ml cefsulodin and 5 µg/ml vancomycin and followed by incubation for 3-5 days at 37°C under microaerophilic conditions. After observing the colonies, they were identified as *H. pylori* if they were catalase, oxidase, and urease positive, with the appearance of Gram negative curved bacilli. Isolates were harvested for storage in Brucella broth containing 20% glycerol and stored at -80°C.

### *DNA extraction from H. pylori isolates*

DNA was extracted from the fresh isolates before storage at -80°C using DNA extraction kit (Roche Co., Germany) according to the manufacturer. After extraction, DNA density was assessed by optic densitometry.

### *Detection of cagA gene using polymerase chain reaction*


All extracted genomic DNA were amplified for *cagA* gene by PCR using automatic thermocy-

cler machine. PCR reactions were performed in a final volume of 25  $\mu$ L containing 2.5  $\mu$ L 10x buffer + Mg<sup>2+</sup>, 0.625 mM/L dNTP (Cinnagene Co., Iran), 2 unit Taq DNA polymerase (Cinnagene CO., Iran), 100 ng from genomic DNA as a template, and 50 Pico mole from each primers of D008 and R008 as described by Covacci et al.<sup>15</sup> These primers (table 1) were used to amplify a fragment of 297 bp from the middle conservative region of the *cagA* gene

(*cagA*).<sup>10</sup> For *cagA*, amplification was performed with 30 cycles of pre-incubation (95°C, 3 minutes), denaturation (94°C, for 1 minutes), annealing (60°C, 2 minutes), extension (72°C, 3 minutes), and a final extension (72°C, 5 minutes). PCR yields were electrophoresed in 1.5% agarose gel (Roche, Germany) containing ethidium bromide. DNA ladder (Roche Co, Germany) was used to detect the molecular weights of observed bands under UV lamp (figure 1).

**Table 1.** Primers used for amplification of *cagA* gene by PCR.

Primers	Sequence (5' → 3')	Product (size, bp)
IcagA D008	ATAATGCTAAATTAGACAACCTTGAGCGA	IcagA (297)
IcagA R008	TTAGAATAATCAACAAACATCACGCCAT	



**Figure 1.** DNA PCR results of *H. pylori*. Lanes 1-4 and 7 were *cag* positive samples and lanes 5 and 6 were *cag* negative *H. pylori* (100 bp DNA ladder).

### Statistics

Results were analyzed using Pearson correlation for assessing the relationship between *cagA* genotype and sex with duodenal ulcer, chronic active gastritis and gastric adenocarcinoma. A one-way analysis of variance (ANOVA) was used to evaluate the difference among the groups. To determine the prediction of education, sex, residence, age and diseases of patients for being positive or negative for *cagA* gene, logistic regression was used.

### Results

*cagA* genotype was obtained using PCR method on 100 clinical samples of *H. pylori*

isolated from patients referred to Alzahra hospital in Isfahan, Iran, with chronic active gastritis, duodenal ulcer and gastric adenocarcinoma. Among these samples, 40 samples were from chronic active gastritis (40%), 40 samples were from duodenal ulcer (40%), and 20 samples were from gastric adenocarcinoma (20%). In the present study, we had 68 positive samples for *cagA* (68%) and 32 samples were negative (32%). Relative frequency of *cagA* genotype of *H. pylori* isolated from gastric biopsies of patients with duodenal ulcer, chronic active gastritis and gastric adenocarcinoma were 72.5%, 65% and 60%, respectively (table 2).

**Table 2.** Frequency of *cagA* genotype of *Helicobacter pylori* in 100 patients biopsy specimens.

Group	<i>cagA</i> genotype				Total
	Positive		Negative		
	Number	Percent (%)	Number	Percent (%)	
Gastritis	26	65	14	35	40
Duodenal ulcer	29	72.5	11	27.5	40
Non-cardia gastric cancer	12	60	8	40	20

From 100 positive samples of *H. pylori* isolates, 60 samples were from men (60%) and 40 samples were from women (40%) (table 3). Mean age for chronic active gastritis, duodenal

ulcer and non-cardia gastric cancer was 44.94, 44.97 and 67.5, respectively. Also, in our study, the sensitivity of RUT (rapid urease test) was 86%.

**Table 3.** Frequency of chronic active gastritis, duodenal ulcer and non-cardia gastric cancer according to sex.

Group	Sex				Total
	Men	Percent	Women	Percent	
Gastritis	20	50%	20	50%	40
Duodenal ulcer	28	70%	12	30%	40
Non-cardia gastric cancer	12	60%	8	40%	20


## Discussion

The presence of *H. pylori* in the gastric mucosa leads to chronic active gastritis and eventually atrophic gastritis and is associated with diseases such as peptic ulcer, non-cardia gastric cancer, and MALT lymphoma.<sup>2,16</sup> There are several factors, which is effective on developing gastric illness in all individuals infected with *H. pylori* such as, environmental condition, host genetic factors and bacterial virulent ability.<sup>17,18</sup> Certain genotypes (e.g., *cagA*, *vacA s1a*) have been closely related to severe clinical outcome and response to anti-*H. pylori* therapy,<sup>19,20</sup> whereas other variants appeared less pathogenic.<sup>19,21</sup> The present study detected the *cagA*, one of the virulence factors of *H. pylori* and association between *cagA* and chronic active gastritis, duodenal ulcer and non-cardia gastric cancer of 100 biopsy specimens from patients referred to Alzahra hospital for endoscopy using PCR. Also, we described the association between presence of *cagA* gene and age and sex of patients. In this study, *cagA* gene was detected in 68% of our patients. The results showed no statistically significant association between *cagA* gene presences with chronic active gastritis, duodenal ulcer and


non-cardia gastric carcinoma. Several recent studies were agreed with our findings that there is no relationship between *cagA* status and clinical symptoms in different patient populations.<sup>22,23</sup> Kamali-Sarvestani and their colleague reported that *cagA* statuses are not significantly different among different disease groups in Shiraz, Iran (a different province).<sup>24</sup> However, other studies have shown that individuals who were colonized with *cagA* positive strains of *H. pylori* are at more risk of gastric ulcer.<sup>8,12,25</sup> The discrepancy between these reports and the results of the present study may have several causes. First, patient selection is extremely important, and the study group should be sufficiently large and diverse with respect to genotypes and clinical symptoms. Second, the geographic origin of the patients may also play an important role. Recent studies suggested the existence of separate bacterial lineage in different parts of the world.<sup>23,25</sup> Third, some studies have investigated the association between *cagA* genes with only one disease such as gastritis, gastric ulcer or duodenal ulcer.<sup>7</sup> We found no significant relationship of *cagA* gene and sex of patients ( $P > 0.05$ , figure 2). Mean age of patients with chronic

active gastritis, duodenal ulcer and non-cardia gastric carcinoma were 44.94, 44.97 and 67.5, respectively. Only in cancer group compared to the other two groups, there were significant differences on frequency of cag positive genotypes among different age groups ( $P < 0.001$ ). Data analysis using logistic regression showed no statistically significant relationship between the presence of the cagA gene and education, sex, residence, age and diseases of

patients ( $P > 0.05$ , figure 3) and none of these factors were predictor for being positive or negative. In summary, the present study showed no significant relationship between cagA genotype of *H. pylori* and chronic active gastritis, duodenal ulcer and non-cardia gastric carcinoma. Prediction of clinical outcome according to cagA genotype isn't helpful. We need further investigations to determine other genes effects like vacA and iceA in our local area.



**Figure 2.** Frequency of cag positive genotype in men and women in chronic active gastritis, duodenal ulcer and non-cardia gastric cancer.



**Figure 3.** Frequency of cag positive genotype according to age in chronic active gastritis, duodenal ulcer and non-cardia gastric cancer.

**Acknowledgements**

This study was supported by vice chancellor

for research affairs of Isfahan University of Medical Sciences.

**References**

- Warburton VJ, Everett S, Mapstone NP, Axon AT, Hawkey P, Dixon MF. **Clinical and histological associations of cagA and vacA genotypes in *Helicobacter pylori* gastritis.** *J Clin Pathol* 1998; 51: 55-61.
- Dunn BE, Cohen H, Blaser MJ. ***Helicobacter pylori*.** *Clin Microbiol Rev* 1997; 10: 720-741.
- Graham DY, Yamaoka Y. **H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications.** *Helicobacter* 1998; 3: 145-151.
- Blaser MJ. **Ecology of *Helicobacter pylori* in the human stomach.** *J Clin Invest* 1997; 100: 759-762.
- Yamaoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K, Graham DY. **Relationship between *Helicobacter pylori* iceA, cagA, and vacA status and clinical outcome: studies in four different countries.** *J Clin Microbiol* 1999; 37: 2274-2279.
- Megraud F. **Pathogenic diversity of *Helicobacter pylori*.** *J Gastroenterol* 1997; 32: 278-281.
- Cover TL. **The vacuolating cytotoxin of *Helicobacter pylori*.** *Mol Microbiol* 1996; 20: 241-246.
- Ribeiro ML, Godoy AP, Benvengo YH, Mendonca S, Pedrazzoli J, Jr. **Clinical relevance of the cagA, vacA and iceA genotypes of *Helicobacter pylori* in Brazilian clinical isolates.** *FEMS Immunol Med Microbiol* 2003; 36: 181-185.
- Perng CL, Lin HJ, Sun IC, Tseng GY, Facq. ***Helicobacter pylori* cagA, iceA and vacA status in Taiwanese patients with peptic ulcer and gastritis.** *J Gastroenterol Hepatol* 2003; 18: 1244-1249.
- Li L, Kelly LK, Ayub K, Graham DY, Go MF. **Genotypes of *Helicobacter pylori* obtained from gastric ulcer patients taking or not taking NSAIDs.** *Am J Gastroenterol* 1999; 94: 1502-1507.
- Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M *et al.* **cag, a pathogenicity island of *Helicobacter pylori*, encodes type I-specific and disease-associated virulence factors.** *Proc Natl Acad Sci USA* 1996; 93: 14648-14653.
- van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, de BW *et al.* **Clinical relevance of the cagA, vacA, and iceA status of *Helicobacter pylori*.** *Gastroenterology* 1998; 115: 58-66.
- Kidd M, Lastovica AJ, Atherton JC, Louw JA. **Conservation of the cag pathogenicity island is associated with vacA alleles and gastroduodenal disease in South African *Helicobacter pylori* isolates.** *Gut* 2001; 49: 11-17.
- Ashour AA, Collares GB, Mendes EN, de G, V, Queiroz DM, Magalhaes PP *et al.* **iceA genotypes of *Helicobacter pylori* strains isolated from Brazilian children and adults.** *J Clin Microbiol* 2001; 39: 1746-1750.
- Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G *et al.* **Molecular characterization of the 128-kDa immunodominant antigen of *Helicobacter pylori* associated with cytotoxicity and duodenal ulcer.** *Proc Natl Acad Sci USA* 1993; 90: 5791-5795.
- Wotherspoon AC. **Gastric MALT lymphoma and *Helicobacter pylori*.** *Yale J Biol Med* 1996; 69: 61-68.
- Graham DY, Malaty HM, Go MF. **Are there susceptible hosts to *Helicobacter pylori* infection?** *Scand J Gastroenterol Suppl* 1994; 205: 6-10.
- Malaty HM, Paykov V, Bykova O, Ross A, Graham DP, Anneger JF *et al.* ***Helicobacter pylori* and socioeconomic factors in Russia.** *Helicobacter* 1996; 1: 82-87.
- Atherton JC. **The clinical relevance of strain types of *Helicobacter pylori*.** *Gut* 1997; 40: 701-703.
- Figueiredo C, van Doorn LJ, Nogueira C, Soares JM, Pinho C, Figueira P *et al.* ***Helicobacter pylori* genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains.** *Scand J Gastroenterol* 2001; 36: 128-135.
- Castillo-Rojas G, Mazari-Hiriart M, Lopez-Vidal Y. **[*Helicobacter pylori*: focus on CagA and VacA major virulence factors].** *Salud Publica Mex* 2004; 46: 538-548.
- Maeda S, Kanai F, Ogura K, Yoshida H, Ikenoue T, Takahashi M *et al.* **High seropositivity of anti-CagA antibody in *Helicobacter pylori*-infected patients irrelevant to peptic ulcers and normal mucosa in Japan.** *Dig Dis Sci* 1997; 42: 1841-1847.
- Ito Y, Azuma T, Ito S, Miyaji H, Hirai M, Yamazaki Y *et al.* **Analysis and typing of the vacA gene from cagA-positive strains of *Helicobacter pylori* isolated in Japan.** *J Clin Microbiol* 1997; 35: 1710-1714.
- Kamali-Sarvestani E, Bazargani A, Masoudian M, Lankarani K, Taghavi AR, Saberifiroozi M. **Association of H pylori cagA and vacA genotypes and IL-8 gene polymorphisms with clinical outcome of infection in Iranian patients with gastrointestinal diseases.** *World J Gastroenterol* 2006; 12: 5205-5210.
- Arents NL, van Zwet AA, Thijs JC, Kooistra-Smid AM, van Slochteren KR, Degener JE *et al.* **The importance of vacA, cagA, and iceA genotypes of *Helicobacter pylori* infection in peptic ulcer disease and gastroesophageal reflux disease.** *Am J Gastroenterol* 2001; 96: 2603-2608.